Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin.
Somatostatin was infused for 5-8 hr into five normal men and eleven normal, conscious dogs. This infusion resulted in a persistent decline in plasma glucagon (40-60%) and insulin (30-45%). Plasma gluccose fell 15-25% during the initial 1-2 hr, but subsequently rose to hyperglycemic levels (130-155 mg/100ml) by 3-6 hr, despite persistent hypoglucagonemia. Glucose production initially declined by 40-50%, but later rose to levels 15-20% above basal rates while peripheral glucose utilization fell to levels 20-30% below basal, thereby accounting for hyperglycemia. Infusion of exogenous insulin so as to restore plasma insulin to preinfusion values or cessation of the somatostatin infusion with restoration of endogenous insulin secretion resulted in a prompt reduction of plasma glucose to baseline values. Prevention of the initial somatostatin-induced hypoglycemic response by intravenous infusion of glucose failed to prevent the delayed hyperglycemia. We conclude that somatostatin caused only transient hypoglycemia in normal subjects and that hyperglycemia eventually developes as a consequence of insulin deficiency. These data indicate that basal glucagon secretion is not essential for the development of fasting hyperglycemia and support the conclusion that insulin deficiency rather than glucagon excess is the primary factor responsible for abnormal glucose homeostasis in the diabetic.
D000328:Adult; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000097:blood*; D004285:Dogs; D005934:Glucagon / Q000097:blood* / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000097:blood* / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D013004:Somatostatin / Q000494:pharmacology*; D013997:Time Factors
D001786:Blood Glucose; D007328:Insulin; D013004:Somatostatin; D005934:Glucagon
J Clin Invest. 1975 May;55(5):1057-66
15959962
Diabetes. 1966 Nov;15(11):778-89
5924611
Am J Physiol. 1956 Sep;187(1):15-24
13362583
J Clin Invest. 1950 Nov;29(11):1421-9
14794768
J Clin Invest. 1971 Aug;50(8):1702-11
5097575
J Clin Invest. 1972 Jul;51(7):1870-8
5032528
J Clin Invest. 1973 Nov;52(11):2774-82
4748510
Diabetes. 1972 Oct;21(10):1013-26
4116300
Lancet. 1974 Oct 26;2(7887):974-7
4138107
Lancet. 1973 Dec 8;2(7841):1299-301
4127645
Nature. 1966 Oct 22;212(5060):355-7
4291146
Lancet. 1976 Jan 31;1(7953):219-21
55531
N Engl J Med. 1974 Sep 12;291(11):544-7
4604408
Lancet. 1975 Jan 4;1(7897):14-6
46337
Science. 1974 Apr 26;184(4135):482-4
4594711
Fed Proc. 1974 Jul;33(7):1855-64
4834189
J Clin Invest. 1974 May;53(5):1481-92
4856884
Science. 1973 Jan 5;179(4068):77-9
4682131
Diabetes. 1976 Feb;25(2):136-51
814024
Science. 1975 Feb 14;187(4176):544-7
1089999
J Clin Invest. 1976 Sep;58(3):761-5
956401
N Engl J Med. 1976 Feb 26;294(9):455-61
1246330
Diabetes. 1976 Feb;25(2):116-21
1248672
Am J Physiol. 1975 Dec;229(6):1662-7
1211499
Metabolism. 1975 Feb;24(2):175-82
1113681
Metabolism. 1971 Apr;20(4):360-72
5550303
Clin Sci. 1961 Aug;21:43-57
13689739